SCHEMBL6583440

SCHEMBL6583440

CCOC(=O)Cc1cccc(SSc2cccc(CC(=O)OCC)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.46
PPARA Q07869 3/20 0.46
L3MBTL1 Q9Y468 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
NPC1 O15118 1/20 0.44
PKM P14618 1/20 0.44
NFKB1 P19838 1/20 0.44
RAB9A P51151 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
PPID Q08752 1/20 0.43
ALDH1A1 P00352 2/20 0.42
MAPK1 P28482 1/20 0.42
F10 P00742 1/20 0.41
CYP4Z1 Q86W10 1/20 0.41
LMNA P02545 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PAM P19021 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16963899 0.89 LMNA (0.49) PPARGPPARAL3MBTL1SMN1; SMN2NPC1
SCHEMBL168556 0.88 PPARG (0.50) PPARGPPARAL3MBTL1SMN1; SMN2NPC1
SCHEMBL68412 0.86 L3MBTL1 (0.50) PPARGPPARAL3MBTL1SMN1; SMN2NPC1
SCHEMBL19346178 0.85 PPARG (0.48) PPARGPPARAL3MBTL1SMN1; SMN2NPC1
SCHEMBL670353 0.84 PPARG (0.47) PPARGPPARAL3MBTL1SMN1; SMN2NPC1
SCHEMBL6586355 0.83 SLC7A5 (0.54) PPARGPPARASMN1; SMN2NPC1PKM
SCHEMBL27544720 0.82 F10 (0.43) PPARGPPARAL3MBTL1SMN1; SMN2NPC1
SCHEMBL1107143 0.81 KMT2A (0.56) L3MBTL1SMN1; SMN2NPC1PKMNFKB1
SCHEMBL1515865 0.81 L3MBTL1 (0.49) PPARGPPARAL3MBTL1SMN1; SMN2NPC1
Bromide SCHEMBL5948962 0.81 L3MBTL1 (0.44) PPARGPPARAL3MBTL1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1307447-B1 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA HOFFMANN LA ROCHE (CH) 2004-12-15 EP disclosed
US-20020188018-A1 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta GONG LEYI (US) 2002-12-12 US disclosed
US-6479490-B2 TREATMENT OF DISEASES CHARACTERIZED BY EXCESS TH2 CYTOKINES AND/ OR AN EXCESS IGE PRODUCTION. SYNTEX (U.S.A.) LLC 2002-11-12 US disclosed
US-20020052397-A1 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta SYNTEX (U.S.A.) LLC 2002-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052397-A1 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta GSK3B, GSK3A, PYGL PPARG 1382/4885PPARA 2473/4885L3MBTL1 4570/4885
US-20020188018-A1 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta GSK3B, GSK3A, PYGL PPARG 2023/4885PPARA 3103/4885L3MBTL1 4448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.